Interventional Cardiology
DAPT duration and strategies post-PCI
Also called DAPT, dual antiplatelet, P2Y12 inhibitors
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
“1/ A-CLOSE Trial: A Close Look PEP: NACE SEP 1: ischemic composite SEP 2: BARC 2,3,5 bleed Active control rate: 5.1% observed vs 7% expected NI margin: 2.3% RD or 1.33 RR Power: 80% Alpha: 1-sided 0.05”
Expert labels are toward A-CLOSE's result, from named public quotes (n=1). As of Nov 10, 2026.
Unverified · drafted by AI from the sources cited below
Dual antiplatelet therapy utilizes platelet aggregation inhibitors, which are agents that antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.1
Risk stratification after percutaneous coronary intervention often involves identifying high bleeding risk patients.1 Complex percutaneous coronary intervention can be defined by any of 6 criteria: 3 vessels treated, ≥3 stents implanted, ≥3 lesions treated, bifurcation with 2 stents implanted, total stent length >60 mm, or chronic total occlusion.2 For stroke, risk and efficacy can be stratified by clinical scores, such as separating patients into an NIHSS 0-3 group or an NIHSS 4-5 group.3
Single or dual antiplatelet therapy is generally preferred for the prevention of ischemic stroke in cases of large-artery atherosclerosis and small-vessel disease.1 In minor stroke patients with scores of NIHSS 0 to 5, dual antiplatelet therapy has been evaluated against alteplase.2 For patients at high bleeding risk undergoing percutaneous coronary intervention, an abbreviated regimen of 1 or 3 months reduced major or clinically relevant non-major bleeding compared to a standard duration of ≥6 months.3 Another trial involving 3005 patients evaluated clopidogrel monotherapy following 1-month dual antiplatelet therapy versus aspirin monotherapy following 12-month dual antiplatelet therapy.4
The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk is still debated.1 It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic protection while limiting bleeding risk compared with dual antiplatelet therapy after complex percutaneous coronary intervention.2 Furthermore, it remains unclear whether clopidogrel is better suited than aspirin as the long-term antiplatelet monotherapy following dual antiplatelet therapy.3
National drug utilisation patterns of antithrombotic and anti-inflammatory therapies: a cross-national comparison between Switzerland and Germany
Swiss Medical Weekly — Kunz M — Nov 2026
Spontaneous recanalization of pediatric internal carotid artery dissection during aspirin monotherapy: a retrospective case series
Child s Nervous System — Tang T — Nov 2026
CCU Journal Club
UCLA #bruinhearts — Wed, Oct 14, 3:00 PM EDT — 1 attended
#bruinhearts VA Journal Club: DAPT MVD
UCLA #bruinhearts — Fri, Aug 14, 11:00 AM EDT — 2 attended
CCU Journal Club: PLATO Trial
UCLA #bruinhearts — Tue, Jul 28, 3:00 PM EDT — 5 attended
Sessions from public communities on Synapse. RSVP to join the live discussion.
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
European Heart Journal — Costa F
146 citations · 2022 · among the most cited on Dual antiplatelet therapy
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions
Journal of the American College of Cardiology — Gragnano F
128 citations · 2023 · among the most cited on Dual antiplatelet therapy
Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke
Journal of the American College of Cardiology — Greco A
119 citations · 2023 · among the most cited on Dual antiplatelet therapy
Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy–Induced Gastrointestinal Injury
Journal of the American College of Cardiology — Han Y
85 citations · 2021 · among the most cited on Dual antiplatelet therapy
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Journal of International Medical Research — Liu H — Nov 2026
“Technical connectivity issues prevented any substantive evaluation of extended dual antiplatelet therapy for multivessel coronary artery disease during the meeting.”
“In stable coronary disease, initial PCI added to optimal medical therapy does not reduce all-cause mortality or myocardial infarction compared to medical therapy alone.”